Sanofi (SNYNF)
| Market Cap | 137.09B |
| Revenue (ttm) | 45.85B |
| Net Income (ttm) | 5.76B |
| Shares Out | n/a |
| EPS (ttm) | 4.60 |
| PE Ratio | 23.82 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14 |
| Average Volume | 15,828 |
| Open | 117.70 |
| Previous Close | 109.84 |
| Day's Range | 109.84 - 117.70 |
| 52-Week Range | 91.34 - 122.03 |
| Beta | 0.46 |
| RSI | 44.58 |
| Earnings Date | Apr 24, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsNews
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent prot...
Sanofi gets FDA nod for its hemophilia treatment
US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents b...
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more long-term promise.
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adu...
Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are becoming the norm.”
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infer...
Sanofi gets priority review for its multiple sclerosis treatment by FDA
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to bo...
Press Release: Availability of the Q1 2025 Aide mémoire
Availability of the Q1 2025 Aide mémoire Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First quart...
Notable healthcare headlines for the week: Pfizer, Sanofi, Sarepta Therapeutics and Medtronic in focus
Sanofi initiated at neutral at Goldman Sachs on need to see pipeline successes
This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Advancing Early Detection in Type 1 Diabetes: Can we get one step ahead? [Promoted content]
On Wednesday 19 March key stakeholders from across the diabetes community gathered in Amsterdam for the 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD). On th...
Wall Street Breakfast Podcast: March Madness Heats Up, Bets Roll In
NCAA March Madness: Watch DraftKings, FanDuel, Robinhood, and Grand Canyon. CoreWeave seeks shares ranging from $47 to $55 in IPO:report. Sanofi strikes autoimmune drug deal for up to $1.9B.
Sanofi strikes autoimmune drug deal for up to $1.9B
Sanofi to acquire Dren Bio's immunology unit
Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.
Press Release: Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune syste...
Press Release: Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune syste...
Sanofi starts production of flu vaccine for next season
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
BRIDGEWATER, N.J. , March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing...
Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
Sanofi NV (NASDAQ: SNY) has been flexing its biotech muscles, and investors are taking notice. The stock is firmly in bullish territory, recently forming a Golden Cross , a classic technical signal t...
Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
Sanofi NV SNY has been flexing its biotech muscles, and investors are taking notice. The stock is firmly in bullish territory, recently forming a Golden Cross , a classic technical signal that often p...
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant...